The extent of the industry's challenge should not be underestimated because it has to prove that the implementation has been inconsistent with the legal 'intent' of the change and the relevant documents are silent on the issue.
The industry's argument will succeed or fail based on the legal intent
September 21, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Former Medicines NZ chair says the time for talk on Pharmac is over
December 5, 2023 - - Latest News -
Ex-TGA head John Skerritt appointed to Medicines Australia board
December 5, 2023 - - BioPharma -
FDA confirms approach to Sofdra NDA resubmission and the materials required
December 4, 2023 - - Australian Biotech -
National Pharmacies opens its first 24-7 pharmacy under South Australian initiative
December 4, 2023 - - Latest News -
PharmAust completes Phase 1 MEND study and files for US Orphan Drug Designation
December 4, 2023 - - Australian Biotech -
OncoSil Medical onboards first patient in the PANCOSIL clinical trial
December 4, 2023 - - Australian Biotech -
Korean regulator approves Amplia Therapeutics' pancreatic cancer trial
December 4, 2023 - - Australian Biotech